Runben Biotechnology Co., Ltd.

SHSE:603193 Stock Report

Market Cap: CN¥7.6b

Runben Biotechnology Future Growth

Future criteria checks 2/6

Runben Biotechnology is forecast to grow earnings and revenue by 17% and 17.2% per annum respectively. EPS is expected to grow by 17% per annum. Return on equity is forecast to be 16.3% in 3 years.

Key information

17.0%

Earnings growth rate

17.03%

EPS growth rate

Personal Products earnings growth19.8%
Revenue growth rate17.2%
Future return on equity16.32%
Analyst coverage

Low

Last updated09 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • Mar 14

Runben Biotechnology (SHSE:603193) Is Reinvesting At Lower Rates Of Return

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
Analysis Article • Feb 10

Earnings Not Telling The Story For Runben Biotechnology Co., Ltd. (SHSE:603193)

There wouldn't be many who think Runben Biotechnology Co., Ltd.'s ( SHSE:603193 ) price-to-earnings (or "P/E") ratio of...
Analysis Article • Dec 15

Do Runben Biotechnology's (SHSE:603193) Earnings Warrant Your Attention?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Aug 03

Estimating The Fair Value Of Runben Biotechnology Co., Ltd. (SHSE:603193)

Key Insights The projected fair value for Runben Biotechnology is CN¥19.83 based on 2 Stage Free Cash Flow to Equity...

Earnings and Revenue Growth Forecasts

SHSE:603193 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20282,549519N/A4793
12/31/20272,188446N/A4254
12/31/20261,858377N/A3884
3/31/20261,572323176292N/A
12/31/20251,545315187275N/A
9/30/20251,518305195298N/A
6/30/20251,469308122250N/A
3/31/20251,392309187271N/A
12/31/20241,318300183257N/A
9/30/20241,247306194242N/A
6/30/20241,198287254265N/A
3/31/20241,048240248258N/A
12/31/20231,033226239253N/A
9/30/2023998209188216N/A
12/31/2022856160125165N/A
12/31/2021582121-13139N/A
12/31/2020443952987N/A
12/31/201927936N/A62N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603193's forecast earnings growth (17% per year) is above the savings rate (2.4%).

Earnings vs Market: 603193's earnings (17% per year) are forecast to grow slower than the CN market (25.9% per year).

High Growth Earnings: 603193's earnings are forecast to grow, but not significantly.

Revenue vs Market: 603193's revenue (17.2% per year) is forecast to grow faster than the CN market (16% per year).

High Growth Revenue: 603193's revenue (17.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603193's Return on Equity is forecast to be low in 3 years time (16.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/27 08:54
End of Day Share Price 2026/07/24 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Runben Biotechnology Co., Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhuonan XuChina International Capital Corporation Limited
Manqi HuangChina International Capital Corporation Limited
Xiaofang XuCitic Securities Co., Ltd.